Gut microbiota translocation promotes autoimmune cholangitis

J Autoimmun. 2018 Dec:95:47-57. doi: 10.1016/j.jaut.2018.09.010. Epub 2018 Oct 17.

Abstract

Gut microbiota and bacterial translocation have been implicated as significant contributors to mucosal immune responses and tolerance; alteration of microbial molecules, termed pathogen-associated molecular patterns (PAMP) and bacterial translocation are associated with immune pathology. However, the mechanisms by which dysregulated gut microbiota promotes autoimmunity is unclear. We have taken advantage of a well-characterized murine model of primary biliary cholangitis, dnTGFβRII mice, and an additional unique construct, toll-like receptor 2 (TLR2)-deficient dnTGFβRII mice coined dnTGFβRIITLR2-/- mice to investigate the influences of gut microbiota on autoimmune cholangitis. Firstly, we report that dnTGFβRII mice manifest altered composition of gut microbiota and that alteration of this gut microbiota by administration of antibiotics significantly alleviates T-cell-mediated infiltration and bile duct damage. Second, toll-like receptor 2 (TLR2)-deficient dnTGFβRII mice demonstrate significant exacerbation of autoimmune cholangitis when their epithelial barrier integrity was disrupted. Further, TLR2-deficiency mediates downregulated expression of tight junction-associated protein ZO-1 leading to increased gut permeability and bacterial translocation from gut to liver; use of antibiotics reduces microbiota translocation to liver and also decreases biliary pathology. In conclusion, our data demonstrates the important role of gut microbiota and bacterial translocation in the pathogenesis of murine autoimmune cholangitis.

Keywords: Bacterial translocation; Fecal bacterial analysis; Gut microbiota; Gut–liver axis; Primary biliary cholangitis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ampicillin / pharmacology
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / microbiology*
  • Autoimmune Diseases / pathology
  • Bacterial Translocation / drug effects
  • Bacterial Translocation / immunology*
  • Bile Ducts / drug effects
  • Bile Ducts / immunology*
  • Bile Ducts / microbiology
  • Bile Ducts / pathology
  • Colon / drug effects
  • Colon / immunology
  • Colon / microbiology
  • Colon / pathology
  • Feces / microbiology
  • Female
  • Gastrointestinal Microbiome / drug effects
  • Gastrointestinal Microbiome / immunology
  • Gene Expression Regulation
  • Immunity, Mucosal / drug effects
  • Liver / drug effects
  • Liver / immunology
  • Liver / microbiology
  • Liver / pathology
  • Liver Cirrhosis, Biliary / drug therapy
  • Liver Cirrhosis, Biliary / immunology*
  • Liver Cirrhosis, Biliary / microbiology
  • Liver Cirrhosis, Biliary / pathology
  • Metronidazole / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neomycin / pharmacology
  • Receptor, Transforming Growth Factor-beta Type II / deficiency
  • Receptor, Transforming Growth Factor-beta Type II / genetics
  • Receptor, Transforming Growth Factor-beta Type II / immunology*
  • Signal Transduction
  • Toll-Like Receptor 2 / deficiency
  • Toll-Like Receptor 2 / genetics
  • Toll-Like Receptor 2 / immunology*
  • Zonula Occludens-1 Protein / genetics
  • Zonula Occludens-1 Protein / immunology

Substances

  • Anti-Bacterial Agents
  • Tjp1 protein, mouse
  • Tlr2 protein, mouse
  • Toll-Like Receptor 2
  • Zonula Occludens-1 Protein
  • Metronidazole
  • Ampicillin
  • Receptor, Transforming Growth Factor-beta Type II
  • Neomycin